Imprimis enters licensing agreement for dry eye formulation

Imprimis Pharmaceuticals has obtained exclusive licensing rights to Klarity, a topical treatment for dry eye disease, according to a company press release.

"The unique chondroitin sulfate-containing Imprimis Klarity eye drops will be especially useful for ocular surface rehabilitation following cataract and other ocular surgery, contact lens wear, trauma and in the dry eye patient with significant symptoms and/or signs such as corneal staining," OSN Chief Medical Editor Richard L. Lindstrom, MD, told Healio.com/OSN.

Klarity, developed by Lindstrom, is a patented ophthalmic topical solution and gel technology designed to treat ocular surface pathology associated with ophthalmic surgery, contact lens wear or patients with moderate to severe dry eye, according to the release.

Under the terms of the licensing agreement, Lindstrom will receive an upfront payment, milestone payments and royalty payments on the sales of Klarity.

Editor's note: This article has been updated to include a quote from Richard L. Lindstrom, MD.